| Literature DB >> 30344581 |
Hasan Ejaz1, Azra Javeed2, Muhammad Zubair3.
Abstract
OBJECTIVE: We determined the bacterial contamination and antibiotic resistance profile of circulating Pakistani currency notes collected from hospital and community sources.Entities:
Keywords: Bacteria; Banknotes; Contamination; Pakistani currency
Year: 2018 PMID: 30344581 PMCID: PMC6191779 DOI: 10.12669/pjms.345.15477
Source DB: PubMed Journal: Pak J Med Sci ISSN: 1681-715X Impact factor: 1.088
Distribution of bacteria among various sources.
| Organism | Sources | Total n (%) | ||||||
|---|---|---|---|---|---|---|---|---|
| Ward boys | Pharmacy | Patient’s attendants | Cafeteria | Butcher’s shops | Vendors | Public transport conductors | ||
| 4 | 2 | 7 | 3 | 4 | 9 | 5 | 34 (26.0) | |
| Coagulase negative | 6 | 0 | 7 | 2 | 4 | 2 | 3 | 24 (18.3) |
| 2 | 1 | 1 | 3 | 4 | 6 | 2 | 19 (14.5) | |
| 1 | 1 | 3 | 0 | 5 | 3 | 5 | 18 (13.7) | |
| 0 | 1 | 4 | 1 | 2 | 5 | 2 | 15 (11.5) | |
| 1 | 0 | 2 | 1 | 1 | 1 | 1 | 7 (5.3) | |
| 2 | 1 | 1 | 0 | 2 | 0 | 1 | 7 (5.3) | |
| 0 | 0 | 1 | 0 | 2 | 0 | 0 | 3 (2.3) | |
| 1 | 0 | 0 | 0 | 1 | 0 | 0 | 2 (1.5) | |
| 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 (0.8) | |
| 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 (0.8) | |
| Total | 17 (13.0%) | 6 (4.6%) | 26 (19.8%) | 11 (8.4%) | 26 (19.8%) | 26 (19.8%) | 19 (14.5%) | 131 (100%) |
Denomination wise distribution of bacterial isolates
| Organisms | Denomination | Total | |||
|---|---|---|---|---|---|
| Rs. 10 | Rs. 20 | Rs. 50 | Rs. 100 | ||
| 12 | 10 | 7 | 5 | 34 | |
| 6 | 5 | 5 | 3 | 19 | |
| 2 | 2 | 3 | 0 | 7 | |
| 10 | 3 | 2 | 0 | 15 | |
| 7 | 5 | 6 | 6 | 24 | |
| 7 | 8 | 2 | 1 | 18 | |
| 2 | 1 | 3 | 1 | 7 | |
| 0 | 0 | 0 | 1 | 1 | |
| 0 | 1 | 0 | 1 | 2 | |
| 0 | 0 | 0 | 1 | 1 | |
| 0 | 1 | 2 | 0 | 3 | |
| Total | 46 | 36 | 30 | 19 | 131 |
Antimicrobial resistance profile of Gram-negative bacteria (n=104).
| Organism | Amikacin n (%) | Co-amoxiclav n (%) | Cefotaxime n (%) | Ceftriaxone n (%) | Ceftazidime n (%) | Cefuroxime n (%) | Cefixime n (%) | Ciprofloxacin n (%) | Imipenem n (%) | Cefoperazone-Sulbactam n (%) | Piperacillin-Tazobactam n (%) | Meropenem n (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 (0.0) | 4 (11.8) | 0 (0.0) | 0 (0.0) | 3 (8.8) | 4 (11.8) | 9 (26.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (5.9) | |
| 0 (0.0) | 0 (0.0) | 1 (5.3) | 0 (0.0) | 0 (0.0) | 1 (5.3) | 0 (0.0) | 1 (5.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (5.3) | |
| 0 (0.0) | 2 (11.1) | 1 (5.6) | 2 (11.1) | 1 (5.6) | 7 (38.9) | 9 (50.0) | 0 (0.0) | 1 (5.6) | 0 (0.0) | 0 (0.0) | 3 (16.7) | |
| 0 (0.0) | 1 (6.7) | 0 (0.0) | 2 (13.3) | 0 (0.0) | 0 (0.0) | 5 (33.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (13.3) | |
| 0 (0.0) | 5 (71.4) | 0 (0.0) | 2 (28.6) | 0 (0.0) | 4 (57.1) | 3 (42.9) | 1 (14.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (14.3) | |
| 0 (0.0) | 0 (0.0) | 2 (28.6) | 0 (0.0) | 0 (0.0) | 5 (71.4) | 3 (42.9) | 1 (14.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Total | 0 (0.0%) | 12 (11.5%) | 4 (3.8%) | 6 (5.8%) | 4 (3.8%) | 21 (20.2%) | 29 (27.9%) | 3 (2.9%) | 1 (1.0%) | 0 (0.0%) | 0 (0.0%) | 9 (8.7%) |
Antimicrobial resistance profile of Gram-positive bacteria (n=27)
| Antibiotic | Coagulase negative Staphylococci (CoNS) n=24 n (%) | Streptococcus spp. n=3 n (%) | Total n (%) |
|---|---|---|---|
| Ampicillin | 14 (58.3) | 3 (100%) | 17 (63.0) |
| Penicillin | 14 (58.3) | 3 (100%) | 17 (63.0) |
| Cefuroxime | 8 (33.3) | 3 (100%) | 11 (40.7) |
| Ceftriaxone | 8 (33.3) | 2 (66.7) | 10 (37.0) |
| Cefixime | 8 (33.3) | 2 (66.7) | 10 (37.0) |
| Ceftazidime | 8 (33.3) | 2 (66.7) | 10 (37.0) |
| Co-amoxiclav | 8 (33.3) | 2 (66.7) | 10 (37.0) |
| Cefotaxime | 8 (33.3) | 0 (0.0) | 8 (29.6) |
| Ciprofloxacin | 7 (29.2) | 1 (33.3) | 8 (29.6) |
| Oxacillin | 8 (33.3) | NA | 8 (33.3) |
| Amikacin | 0 (0.0) | 2 (66.7) | 2 (7.4) |
| Gentamicin | 0 (0.0) | 2 (66.7) | 2 (7.4) |
| Linezolid | 2 (8.3) | 0 (0.0) | 2 (7.4) |
| Vancomycin | 1 (4.2) | 0 (0.0) | 1 (3.7) |
NA: Not Applied